Credit Suisse Ag Adicet Bio, Inc. Transaction History

Credit Suisse Ag

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	BUY	$5.52 - $9.23 $27 - $46	5 Added 0.04%	13,358 $76,000
Q4 2022 Feb 13, 2023	SELL	$7.72 - $21.27 $5,326 - $14,676	-690 Reduced 4.91%	13,353 $119,000
Q3 2022 Nov 10, 2022	BUY	$13.43 - $18.74 $1,786 - $2,492	133 Added 0.96%	14,043 $200,000
Q2 2022 Aug 12, 2022	BUY	$10.26 - $20.81 $142,716 - $289,467	13,910 New	13,910 $203,000

59.2M

4.2K

6.7K

Ticker ACET
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,030,800
Market Cap $36M
Description
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.